Universidade Federal do Ceara
Quick facts
Marketed products
- chlorhexidine digluconate · Infectious Disease / Oral Care
Chlorhexidine digluconate is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, leading to rapid bactericidal and bacteriostatic effects.
Phase 3 pipeline
- NAC + Bromhexine (BMX) · Respiratory/Pulmonology
NAC and bromhexine work synergistically to reduce mucus viscosity and promote clearance while providing antioxidant and anti-inflammatory effects.
Phase 2 pipeline
- chlorexidine · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Universidade Federal do Ceara
What are Universidade Federal do Ceara's marketed drugs?
Top marketed products include chlorhexidine digluconate.
What is Universidade Federal do Ceara's pipeline?
Universidade Federal do Ceara has 1 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include NAC + Bromhexine (BMX).
Related
- chlorhexidine digluconate · Infectious Disease / Oral Care
- Sector hub: All tracked pharma companies